P2RY12 and atrial fibrillation: Based on the current evidence, current European guidelines [2] recommend an initial period of 1 week of TAT, followed by 12 months of a P2Y12 inhibitor, preferably clopidogrel, in combination with OAC for patients with AF and ACS undergoing uncomplicated PCI, provided the risk of thrombosis is low and the bleeding risk is high (class of recommendation I, level of evidence A).